vs
豪洛捷（HOLX）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
豪洛捷的季度营收约是Revvity的1.4倍（$1.0B vs $772.1M），豪洛捷净利率更高（17.1% vs 12.7%，领先4.4%），Revvity同比增速更快（5.9% vs 2.5%），豪洛捷自由现金流更多（$215.2M vs $161.8M），过去两年Revvity的营收复合增速更高（9.0% vs 1.5%）
豪洛捷是一家总部位于美国的医疗科技企业，核心业务聚焦女性健康领域，旗下产品涵盖诊断、外科手术及医学影像类专业医疗设备，为全球各地的医疗场景提供优质技术与产品支持。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
HOLX vs RVTY — 直观对比
营收规模更大
HOLX
是对方的1.4倍
$772.1M
营收增速更快
RVTY
高出3.3%
2.5%
净利率更高
HOLX
高出4.4%
12.7%
自由现金流更多
HOLX
多$53.4M
$161.8M
两年增速更快
RVTY
近两年复合增速
1.5%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.0B | $772.1M |
| 净利润 | $179.1M | $98.4M |
| 毛利率 | 56.0% | — |
| 营业利润率 | 22.6% | 14.5% |
| 净利率 | 17.1% | 12.7% |
| 营收同比 | 2.5% | 5.9% |
| 净利润同比 | -10.9% | 3.9% |
| 每股收益（稀释后） | $0.79 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HOLXRVTY
| Q4 25 | $1.0B | $772.1M | ||
| Q3 25 | $1.0B | $698.9M | ||
| Q2 25 | $1.0B | $720.3M | ||
| Q1 25 | $1.0B | $664.8M | ||
| Q4 24 | $1.0B | $729.4M | ||
| Q3 24 | $988.0M | $684.0M | ||
| Q2 24 | $1.0B | $691.7M | ||
| Q1 24 | $1.0B | $649.9M |
净利润HOLXRVTY
| Q4 25 | $179.1M | $98.4M | ||
| Q3 25 | $187.2M | $46.7M | ||
| Q2 25 | $194.9M | $53.9M | ||
| Q1 25 | $-17.4M | $42.2M | ||
| Q4 24 | $201.0M | $94.6M | ||
| Q3 24 | $178.6M | $94.4M | ||
| Q2 24 | $194.5M | $55.4M | ||
| Q1 24 | $169.9M | $26.0M |
毛利率HOLXRVTY
| Q4 25 | 56.0% | — | ||
| Q3 25 | 55.6% | 53.6% | ||
| Q2 25 | 56.3% | 54.5% | ||
| Q1 25 | 37.5% | 56.5% | ||
| Q4 24 | 56.8% | — | ||
| Q3 24 | 56.4% | 56.3% | ||
| Q2 24 | 55.4% | 55.7% | ||
| Q1 24 | 53.3% | 54.6% |
营业利润率HOLXRVTY
| Q4 25 | 22.6% | 14.5% | ||
| Q3 25 | 22.6% | 11.7% | ||
| Q2 25 | 24.9% | 12.6% | ||
| Q1 25 | -0.7% | 10.9% | ||
| Q4 24 | 22.5% | 16.3% | ||
| Q3 24 | 23.3% | 14.3% | ||
| Q2 24 | 24.1% | 12.4% | ||
| Q1 24 | 20.7% | 6.8% |
净利率HOLXRVTY
| Q4 25 | 17.1% | 12.7% | ||
| Q3 25 | 17.8% | 6.7% | ||
| Q2 25 | 19.0% | 7.5% | ||
| Q1 25 | -1.7% | 6.4% | ||
| Q4 24 | 19.7% | 13.0% | ||
| Q3 24 | 18.1% | 13.8% | ||
| Q2 24 | 19.2% | 8.0% | ||
| Q1 24 | 16.7% | 4.0% |
每股收益（稀释后）HOLXRVTY
| Q4 25 | $0.79 | $0.86 | ||
| Q3 25 | $0.84 | $0.40 | ||
| Q2 25 | $0.86 | $0.46 | ||
| Q1 25 | $-0.08 | $0.35 | ||
| Q4 24 | $0.87 | $0.77 | ||
| Q3 24 | $0.75 | $0.77 | ||
| Q2 24 | $0.82 | $0.45 | ||
| Q1 24 | $0.72 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.4B | $919.9M |
| 总债务越低越好 | $2.5B | — |
| 股东权益账面价值 | $5.2B | $7.3B |
| 总资产 | $9.2B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.48× | — |
8季度趋势，按日历期对齐
现金及短期投资HOLXRVTY
| Q4 25 | $2.4B | $919.9M | ||
| Q3 25 | $2.2B | $931.4M | ||
| Q2 25 | $1.9B | $991.8M | ||
| Q1 25 | $1.6B | $1.1B | ||
| Q4 24 | $2.0B | $1.2B | ||
| Q3 24 | $2.3B | $1.2B | ||
| Q2 24 | $2.4B | $2.0B | ||
| Q1 24 | $2.2B | $1.7B |
总债务HOLXRVTY
| Q4 25 | $2.5B | — | ||
| Q3 25 | $2.5B | — | ||
| Q2 25 | $2.5B | — | ||
| Q1 25 | $2.5B | — | ||
| Q4 24 | $2.5B | — | ||
| Q3 24 | $2.5B | — | ||
| Q2 24 | $2.5B | — | ||
| Q1 24 | $2.6B | — |
股东权益HOLXRVTY
| Q4 25 | $5.2B | $7.3B | ||
| Q3 25 | $5.0B | $7.4B | ||
| Q2 25 | $4.8B | $7.6B | ||
| Q1 25 | $4.6B | $7.6B | ||
| Q4 24 | $4.8B | $7.7B | ||
| Q3 24 | $5.1B | $7.9B | ||
| Q2 24 | $5.0B | $7.9B | ||
| Q1 24 | $4.8B | $7.8B |
总资产HOLXRVTY
| Q4 25 | $9.2B | $12.2B | ||
| Q3 25 | $9.0B | $12.1B | ||
| Q2 25 | $8.8B | $12.4B | ||
| Q1 25 | $8.5B | $12.4B | ||
| Q4 24 | $8.7B | $12.4B | ||
| Q3 24 | $9.2B | $12.8B | ||
| Q2 24 | $8.9B | $13.4B | ||
| Q1 24 | $8.7B | $13.4B |
负债/权益比HOLXRVTY
| Q4 25 | 0.48× | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | 0.52× | — | ||
| Q1 25 | 0.55× | — | ||
| Q4 24 | 0.53× | — | ||
| Q3 24 | 0.49× | — | ||
| Q2 24 | 0.51× | — | ||
| Q1 24 | 0.53× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $229.9M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $215.2M | $161.8M |
| 自由现金流率自由现金流/营收 | 20.5% | 21.0% |
| 资本支出强度资本支出/营收 | 1.4% | 2.6% |
| 现金转化率经营现金流/净利润 | 1.28× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $1.0B | $509.4M |
8季度趋势，按日历期对齐
经营现金流HOLXRVTY
| Q4 25 | $229.9M | $182.0M | ||
| Q3 25 | $355.1M | $138.5M | ||
| Q2 25 | $343.3M | $134.3M | ||
| Q1 25 | $169.4M | $128.2M | ||
| Q4 24 | $189.3M | $174.2M | ||
| Q3 24 | $367.0M | $147.9M | ||
| Q2 24 | $405.8M | $158.6M | ||
| Q1 24 | $292.4M | $147.6M |
自由现金流HOLXRVTY
| Q4 25 | $215.2M | $161.8M | ||
| Q3 25 | $341.4M | $120.0M | ||
| Q2 25 | $330.5M | $115.5M | ||
| Q1 25 | $153.9M | $112.2M | ||
| Q4 24 | $172.5M | $149.8M | ||
| Q3 24 | $350.6M | $125.6M | ||
| Q2 24 | $385.3M | $136.6M | ||
| Q1 24 | $279.6M | $129.7M |
自由现金流率HOLXRVTY
| Q4 25 | 20.5% | 21.0% | ||
| Q3 25 | 32.5% | 17.2% | ||
| Q2 25 | 32.3% | 16.0% | ||
| Q1 25 | 15.3% | 16.9% | ||
| Q4 24 | 16.9% | 20.5% | ||
| Q3 24 | 35.5% | 18.4% | ||
| Q2 24 | 38.1% | 19.7% | ||
| Q1 24 | 27.5% | 20.0% |
资本支出强度HOLXRVTY
| Q4 25 | 1.4% | 2.6% | ||
| Q3 25 | 1.3% | 2.6% | ||
| Q2 25 | 1.3% | 2.6% | ||
| Q1 25 | 1.5% | 2.4% | ||
| Q4 24 | 1.6% | 3.4% | ||
| Q3 24 | 1.7% | 3.3% | ||
| Q2 24 | 2.0% | 3.2% | ||
| Q1 24 | 1.3% | 2.7% |
现金转化率HOLXRVTY
| Q4 25 | 1.28× | 1.85× | ||
| Q3 25 | 1.90× | 2.97× | ||
| Q2 25 | 1.76× | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | 0.94× | 1.84× | ||
| Q3 24 | 2.05× | 1.57× | ||
| Q2 24 | 2.09× | 2.87× | ||
| Q1 24 | 1.72× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
